Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Frequency and Abundance of ALK/ROS1/MET Mutations on Circulating Tumor DNA in Patients With Non-small Cell Lung Cancer Using Single Molecule Amplifcation and Re-sequencing Technology: a Perspective Observational Study

NCT02946216 is registered in ClinicalTrials.gov with First People's Hospital of Hangzhou as lead sponsor.

NCT NCT02946216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02946216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Frequency and Abundance of ALK/ROS1/MET Mutations on Circulating Tumor DNA in Patients With Non-small Cell Lung Cancer Using Single Molecule Amplifcation and Re-sequencing Technology: a Perspective Observational Study
Lead sponsor
First People's Hospital of Hangzhou
Phase
Observational
Overall status
Unknown status
Start date
November 30, 2016
Completion date
November 30, 2018
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of lung, egfr wildtype, non-small cell lung cancer stage iii, non-small-cell lung cancer metastatic